< Back to All Events

Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

September 7, 2022 8:00 AM
Click here for webcast

NEWARK, Calif., August 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA. Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a company panel for targeted oncology on Thursday, September 8 at 2:40-3:25 PM ET. The webcast of the panel is linked here. If you would like to request a meeting with management, please contact your Citi representative.